Jincai Zhong

机构：Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University · ORCID：0000-0002-2543-2788

发表论文 11 篇 · 总被引 217 次 · h-index 3

代表论文

• Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2023 · The Lancet Oncology · 被引 107)
• Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial (2023 · BMJ · 被引 88)
• TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study (2025 · Cancer Cell · 被引 10)
• Prognostic factors of patients after liver cancer surgery (2021 · Medicine · 被引 3)
• ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer. (2025 · Journal of Clinical Oncology · 被引 2)
• SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort. (2025 · Journal of Clinical Oncology · 被引 1)